A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-BGB-16673 Following a Single Oral Dose in Healthy Male Participants
Latest Information Update: 20 Jun 2025
At a glance
- Drugs BGB-16673 (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Pharmacokinetics
- Sponsors BeiGene; BeOne Medicines
Most Recent Events
- 27 May 2025 According to BeOne Medicines media release, BeiGene is now called BeOne Medicines
- 27 Apr 2025 Status changed from recruiting to completed.
- 18 Feb 2025 Status changed from not yet recruiting to recruiting.